Compare CAC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | OMER |
|---|---|---|
| Founded | 1875 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.2M | 844.6M |
| IPO Year | 1996 | 2008 |
| Metric | CAC | OMER |
|---|---|---|
| Price | $57.18 | $19.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $47.00 | $32.50 |
| AVG Volume (30 Days) | 71.1K | ★ 2.3M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | 6.08 | ★ 98.15 |
| EPS | ★ 2.64 | 0.77 |
| Revenue | ★ $41,739,000.00 | $29,868,000.00 |
| Revenue This Year | $19.15 | N/A |
| Revenue Next Year | $6.05 | $233.22 |
| P/E Ratio | ★ $21.70 | $24.83 |
| Revenue Growth | ★ 16.96 | N/A |
| 52 Week Low | $35.00 | $3.94 |
| 52 Week High | $60.59 | $19.65 |
| Indicator | CAC | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 73.82 |
| Support Level | $56.91 | $18.00 |
| Resistance Level | $60.07 | $19.65 |
| Average True Range (ATR) | 2.18 | 0.81 |
| MACD | -0.05 | -0.19 |
| Stochastic Oscillator | 62.41 | 85.47 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.